Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201625 | 1.00 | RAB9A (0.71) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL8584136 | 0.90 | GSK3B (0.61) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL29985867 | 0.90 | GSK3B (0.61) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL1753283 | 0.90 | RAB9A (0.85) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL8044783 | 0.83 | NPC1 (0.68) | RAB9ANPC1L3MBTL1MAPTLMNA | |
| SCHEMBL10649146 | 0.83 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL5725840 | 0.83 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL7854876 | 0.83 | NPC1 (0.68) | RAB9ANPC1L3MBTL1MAPTLMNA | |
| SCHEMBL1393818 | 0.83 | L3MBTL1 (0.76) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL11687127 | 0.82 | MAPT (0.60) | RAB9ANPC1L3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479575-B2 | Method for preparing para-phenyl alkynyl benzaldehydes | LABORATOIRES SERONO SA (CH) | 2009-01-20 | — | — | US | disclosed |
| US-7479575-B2 | Method for preparing para-phenyl alkynyl benzaldehydes | LABORATOIRES SERONO SA (CH) | 2009-01-20 | — | — | US | disclosed |
| US-20080108849-A1 | Method For Preparing Para-Phenyl Alkynyl Benzaldehydes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-05-08 | — | — | US | disclosed |
| US-20080108849-A1 | Method For Preparing Para-Phenyl Alkynyl Benzaldehydes | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-05-08 | — | — | US | disclosed |
| EP-1675813-B1 | METHOD FOR PREPARING PARA-PHENYL ALKYNYL BENZALDEHYDES | SERONO LAB (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007086080-A2 | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-08-02 | — | — | WO | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| CN-1681763-A | Chemical compounds | ASTRAZENECA AB (SE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1580191-A1 | PROCESS FOR PRODUCING CARBAPENEM COMPOUND FOR ORAL ADMINISTRATION | KANEKA CORPORATION (JP) | 2005-09-28 | — | — | EP | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108849-A1 | Method For Preparing Para-Phenyl Alkynyl Benzaldehydes | TNNC1, CPT1B, MUSK | RAB9A 2016/4885NPC1 3688/4885L3MBTL1 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.